Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to -$58.6 million.

  • Protagonist Therapeutics' Cash from Investing Activities rose 71.94% to -$58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.9 million, marking a year-over-year increase of 69.64%. This contributed to the annual value of -$299.5 million for FY2024, which is 662.86% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Cash from Investing Activities stood at -$58.6 million for Q3 2025, which was down 206.83% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Cash from Investing Activities ranged from a high of $57.3 million in Q3 2022 and a low of -$208.7 million during Q3 2024.
  • Its 3-year average for Cash from Investing Activities is -$39.7 million, with a median of -$13.6 million in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 346.85% in 2022, then slumped by 1,657.48% in 2023.
  • Protagonist Therapeutics' Cash from Investing Activities (Quarterly) stood at $27.9 million in 2021, then tumbled by 85.88% to $3.9 million in 2022, then slumped by 1,657.48% to -$61.3 million in 2023, then skyrocketed by 85.76% to -$8.7 million in 2024, then surged by 71.94% to -$58.6 million in 2025.
  • Its Cash from Investing Activities was -$58.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and -$94.4 million in Q1 2025.